title: Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease.
abstract: To test the hypothesis that Alzheimer's disease (AD) patients with posterior cingulate/precuneus (PCP) atrophy would be a distinct disease form in view of metabolic decline. Eighty-one AD patients underwent (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and structural magnetic resonance imaging (MRI). Positron emission tomography and voxel-based morphometry (VBM) Z-score maps were generated for the individual patients using age-specific normal databases. The patients were classified into 3 groups based on atrophic patterns (no-Hipp-PCP, atrophy in neither hippocampus nor PCP; Hipp, hippocampal atrophy; PCP, PCP atrophy). There were 16 patients classified as no-Hipp-PCP, 55 as Hipp, and 10 as PCP. The Mini Mental State Examination (MMSE) score was similar among the groups. The greater FDG decline than atrophy was observed in all groups, including the no-Hipp-PCP. The PCP group was younger, and was associated with a greater degree of FDG decline in PCP than the others. There are diverse atrophic patterns in a spectrum of AD. In particular, a subset of patients show PCP atrophy, which is associated with greater metabolic burden.
authors.affiliation: Department of Neurology and Neurobiology of Aging, Kanazawa University, Graduate School of Medical Science, Kanazawa, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Shima
authors.forename: Ichiro
authors.initials: I
authors.lastname: Matsunari
authors.forename: Miharu
authors.initials: M
authors.lastname: Samuraki
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Chen
authors.forename: Daisuke
authors.initials: D
authors.lastname: Yanase
authors.forename: Moeko
authors.initials: M
authors.lastname: Noguchi-Shinohara
authors.forename: Nozomi
authors.initials: N
authors.lastname: Takeda
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Ono
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Yoshita
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsuda
authors.forename: Masahito
authors.initials: M
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000097:blood / Q000134:cerebrospinal fluid; D001057:Apolipoproteins E / Q000235:genetics; D001284:Atrophy / Q000000981:diagnostic imaging / Q000209:etiology / Q000473:pathology; D001288:Attention; D001931:Brain Mapping; D003071:Cognition; D005260:Female; D019788:Fluorodeoxyglucose F18; D006179:Gyrus Cinguli / Q000000981:diagnostic imaging / Q000473:pathology*; D006801:Humans; D007858:Learning; D008279:Magnetic Resonance Imaging; D008297:Male; D008609:Mental Status Schedule; D008659:Metabolic Diseases / Q000000981:diagnostic imaging / Q000209:etiology*; D008875:Middle Aged; D009483:Neuropsychological Tests; D010446:Peptide Fragments / Q000097:blood / Q000134:cerebrospinal fluid; D049268:Positron-Emission Tomography
chemical_list: D016229:Amyloid beta-Peptides; D001057:Apolipoproteins E; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D019788:Fluorodeoxyglucose F18